MX2016007066A - Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. - Google Patents

Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.

Info

Publication number
MX2016007066A
MX2016007066A MX2016007066A MX2016007066A MX2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A MX 2016007066 A MX2016007066 A MX 2016007066A
Authority
MX
Mexico
Prior art keywords
wnt pathway
identification
pathway inhibitors
biomarkers associated
predictive biomarkers
Prior art date
Application number
MX2016007066A
Other languages
English (en)
Spanish (es)
Inventor
M Kapoun Ann
Zhang Chun
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2016007066A publication Critical patent/MX2016007066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016007066A 2013-12-02 2014-12-02 Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. MX2016007066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US201461975339P 2014-04-04 2014-04-04
PCT/US2014/068097 WO2015084808A1 (fr) 2013-12-02 2014-12-02 Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt

Publications (1)

Publication Number Publication Date
MX2016007066A true MX2016007066A (es) 2016-09-08

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007066A MX2016007066A (es) 2013-12-02 2014-12-02 Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.

Country Status (9)

Country Link
EP (1) EP3077546A4 (fr)
JP (1) JP2017501137A (fr)
CN (1) CN105829547A (fr)
AU (1) AU2014357354A1 (fr)
CA (1) CA2931975A1 (fr)
HK (1) HK1223657A1 (fr)
MX (1) MX2016007066A (fr)
TW (1) TW201610168A (fr)
WO (1) WO2015084808A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2950885B1 (fr) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance de traitement par un inhibiteur de la voie wnt
WO2017023971A1 (fr) * 2015-08-03 2017-02-09 Oncomed Pharmaceuticals, Inc. Identification de biomarqueurs prédictifs associés à des inhibiteurs de la voie wnt
CN108289881A (zh) * 2015-09-16 2018-07-17 妥必徕疗治公司 用于治疗纤维化的赛尼克韦罗联合疗法
AU2017347822A1 (en) * 2016-10-26 2019-05-09 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody
CN106990245B (zh) * 2017-04-05 2018-07-31 东南大学 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110835372B (zh) * 2019-11-06 2020-12-01 上海健康医学院 一种靶向Frizzled7单克隆抗体及其制备方法与应用
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN115337400A (zh) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 诊断和治疗肿瘤的试剂及其用途
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
WO2023113013A1 (fr) * 2021-12-17 2023-06-22 国立大学法人京都大学 Procédé de sélection d'un gène destiné à être utilisé dans l'estimation de la possibilité d'apparition d'une maladie, et procédé d'estimation de la possibilité d'apparition d'une maladie

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO2001002568A2 (fr) * 1999-07-02 2001-01-11 Chiron Corporation Nouveaux genes humains et produits d'expression genique
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP1355919B1 (fr) 2000-12-12 2010-11-24 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1549144A4 (fr) * 2002-10-04 2010-01-06 Univ California Methodes de traitement du cancer par inhibition de la signalisation de wnt
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2545603A1 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
WO2005075514A2 (fr) 2004-03-10 2005-08-18 Lonza Ltd. Procede de production d'anticorps
CA2581208A1 (fr) 2004-08-30 2006-03-09 Lonza Biologics Plc. Chromatographie par echange d'ions et affinite pour la purification d'anticorps
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AR062709A1 (es) 2006-09-08 2008-11-26 Genentech Inc Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt
US20100130374A1 (en) * 2006-09-29 2010-05-27 Annuska Maria Glas High-throughput diagnostic testing using arrays
WO2008042236A2 (fr) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions et procédés permettant de diagnostiquer et de traiter le cancer
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092010A1 (fr) 2008-01-18 2009-07-23 Gagnon Peter S Purification améliorée de biomolécules phosphorylées et non phosphorylées par chromatographie sur hydroxyapatite
WO2010037041A2 (fr) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
WO2010101793A2 (fr) * 2009-03-06 2010-09-10 University Of South Alabama Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011205409B2 (en) 2010-01-12 2015-08-20 Oncomed Pharmaceuticals, Inc. Wnt-binding agents and uses thereof
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法

Also Published As

Publication number Publication date
TW201610168A (zh) 2016-03-16
CA2931975A1 (fr) 2015-06-11
HK1223657A1 (zh) 2017-08-04
JP2017501137A (ja) 2017-01-12
WO2015084808A1 (fr) 2015-06-11
WO2015084808A4 (fr) 2015-08-13
CN105829547A (zh) 2016-08-03
AU2014357354A1 (en) 2016-06-09
EP3077546A1 (fr) 2016-10-12
EP3077546A4 (fr) 2017-04-26

Similar Documents

Publication Publication Date Title
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
IL261353A (en) idh1 suppressors for the treatment of hematological malignancies and solid tumors
PH12017500293A1 (en) Boronic acid derivatives
HK1213189A1 (zh) 預防腫瘤轉移、癌症治療和預後及鑒定為推定轉移抑制劑的試劑的方法
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
EP3394032A4 (fr) Composés et méthodes de traitement, de dépistage, et d'identification de composés destinés à traiter les maladies provoquées par des parasites apicomplexes
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
MX2015014660A (es) Vigilancia de tratamiento y pronóstico de los trastornos de la proliferación utilizando inhibidores de la vía de hedgehog.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX2014011500A (es) Diagnosticos y tratamientos relacionados a inhibidores her3.
MX2015011428A (es) Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TN2019000212A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
MX2015016305A (es) Biomarcador predictivo para terapia contra el cancer.
BR112016025040A2 (pt) métodos para determinar a expressão de biomarcador mit, para tratar câncer, para identificar um indivíduo com câncer, para predizer se um indivíduo com câncer tem mais ou menos probabilidade de responder efetivamente ao tratamento, para inibir a proliferação de uma célula e para tratar nccrcc em um indivíduo
MA40636A (fr) Procédés pour détecter le cancer de la prostate
JO3730B1 (ar) استخدام مثبطات fgfr شاملة وطريقة لتعيين مرضى لديهم سرطان مؤهلين للمعالجة مع مثبط fgfr شامل
IL249741A0 (en) Identification of cancer stem cell markers and their use for detection and treatment
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
NZ740817A (en) Pcna inhibitors
MX2015010776A (es) Metodos y composiciones para detectar y tratar mutantes de akt resistentes a farmacos.